Company Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer.

Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG).

enGene Holdings Inc. is based in Montreal, Canada.

enGene Holdings Inc.

Country	Canada
Founded	1999
Industry	Biotechnology
Sector	Healthcare
Employees	57
CEO	Ronald H. Cooper

Contact Details

Address: 4868 Rue Levy, Suite 220 Montreal, QC H4R 2P1 Canada
Phone	514 332 4888
Website	engene.com

Stock Details

Ticker Symbol	ENGN
Exchange	NASDAQ
Share Class	Class A Shares
Fiscal Year	November - October
Reporting Currency	USD
CIK Code	1980845
CUSIP Number	46429B226
ISIN Number	CA29286M1059
SIC Code	2836

Key Executives

Name	Position
Ronald H. W. Cooper	President, Chief Executive Officer and Director
Dr. Anthony T. Cheung Ph.D.	Co-Founder and Chief Scientific Officer
David Ryan Daws	Chief Financial Officer and Head of Business Development
Dr. Alexander Nichols Ph.D.	Chief Strategy and Operations Officer
Joan Connolly	Chief Technology Officer
Lee G. Giguere	Chief Legal Officer and Corporate Secretary
Tara Place M.B.A.	Senior Vice President of Human Resources
Matthew Boyd	Chief Regulatory Officer
Jill Buck	Chief Development Officer
Amy Pott	Chief Global Commercialization Officer

Latest SEC Filings

Date	Type	Title
Nov 18, 2025	SCHEDULE 13G	Filing
Nov 18, 2025	SCHEDULE 13G	Filing
Nov 14, 2025	8-K	Current Report
Nov 14, 2025	SCHEDULE 13G/A	Filing
Nov 14, 2025	424B5	Filing
Nov 12, 2025	424B5	Filing
Nov 12, 2025	8-K	Current Report
Oct 2, 2025	8-K	Current Report
Oct 2, 2025	8-K/A	[Amend] Current report
Sep 30, 2025	8-K	Current Report

View All SEC Filings